Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Journal Title: Iranian Journal of Blood and Cancer - Year 2015, Vol 7, Issue 4
Abstract
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been detected to have increased expression in many cancers. We aimed to determine if SIRT1expression could play a role in the emergence of drug resistance in patients with chronic myeloid leukemia being treated with imatinib mesylate. Methods: 48 patients with chronic myeloid leukemia referred to Dr. Shariati Hospital, Tehran, Iran, were studied. A venous blood sample of patients was collected, RNA was extracted and then cDNA were synthesized. SIRT1 gene expression was done by real-time PCR. The ratio of SIRT1 expression to ABL control gene was calculated. After calculation of CT for target gene and control gene, &DeltaCT was calculated. The results of SIRT1 expression levels in patients with chronic phase of CML were compared with that of the control group. Results: 48 patients with chronic myeloid leukemia aged 15-64 years (mean: 40 years) were enrolled. 59% of the participants were men. The highest and lowest mean BCR-ABL expressions in drug-resistant patients were 1% and 57%, respectively. The results of analyzing the value of &DeltaCT for SIRT1 gene revealed that patients who were drug-resistant to imatinib mesylate had a lower value of &DeltaCT for SIRT1 than those who were not drug-resistant (P<0.05). Conclusion: SIRT1 gene expression in patients resistant to imatinib mesylate was significantly higher than patients who were not drug-resistant.
Authors and Affiliations
Abbas Ghotaslou, Sadegh Abbasian, Ali Ghasemi, F Nadali
Keywords
Related Articles
- EP ID EP281553
- DOI -
- Views 106
- Downloads 0
Patients Perspective in Plasma Products (Focus on Hemophilia)
Effective treatment of inherited bleeding disorders has become available from plasma in the last 50 years. Plasma-derived medicinal products are used in Iran in a wide variety of clinical problems. Some of these...
Clinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological...
Short-term Chelating Efficacy of Deferoxamine in Iron Overloaded Rat Hepatocytes
Abstract Background: Iron overload is a clinical consequence of repeated blood transfusions and causes significant organ damage, morbidity, and mortality in the absence of proper treatment. The primary targets of Iron ch...
Hemoglobin E/β⁰ Thalassemia in south west Iran - A case series
Background: Beta thalassemia gene mutations are among common mutations in southwest Iran. However, Hemoglobin E (Hb E) and Hb E/β⁰ thalassemia account for a small number of hemoglobinopathies in Iran. This is the first s...
Health-Related Quality of Life and Predictive Role of Self-Efficacy in Iranian Patients with Sickle Cell Disease
Background: Although several studies have been done on quality of life of patients with Sickle Cell Disease (SCD), there is little research on the correlation of health-related quality of life (HRQoL) with self-efficacy...